Wolfgang Miesbach: Predicting Breakthrough Bleeding in Emicizumab-Treated Acquired Haemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
“Predicting Breakthrough Bleeding in Emicizumab-Treated Acquired Haemophilia A. Excellent work presented at ASH2025 by Fabius Pelzer addressing one of the most pressing challenges in acquired haemophilia A:
Despite emicizumab’s remarkable efficacy in preventing bleeds, up to 30% of patients still experience breakthrough bleeding—and we currently lack reliable predictive tools to identify who’s at risk.
This changes today.
Using FXIa-triggered thrombin generation (FXIa-TGA) as a surrogate biomarker, Pelzer and colleagues developed an innovative nomogram to assess individual bleeding risk based on:
- Peak thrombin generation potential
- Emicizumab levels
- Residual Factor VIII activity
Main findings:
- FXIa-TGA peak thrombin is more sensitive than conventional TGA to low factor levels and emicizumab concentrations
- Both emicizumab and residual Factor VIII significantly influence peak thrombin generation in the multivariable model
- Higher peak thrombin values correlated with lower bleeding rates (IRR 0.40 [0.17-0.84])
This is precision haemostasis and enables patient-specific risk stratification in real time. Moving beyond one-size-fits-all dosing to truly personalized management of AHA.
Having a functional biomarker that predicts individual risk opens pathways for:
- Optimized prophylactic dosing strategies
- Early detection of patients requiring intervention
- Better understanding of emicizumab mechanism in real-world AHA
Congratulations to Fabius, Andreas Tiede and the entire GTH study team on this rigorous work that has now been published in Haematologica Journal.”
Read more posts from Wolfgang Miesbach on Hemostasis Today.
-
Apr 6, 2026, 13:45Svenja Tatjana Barckhausen: From Plasma Dependence to Self-Sufficiency in Africa
-
Apr 6, 2026, 13:35Gregory Piazza: When Antibodies Trigger Thrombosis
-
Apr 6, 2026, 13:24Paritosh Garg: Importance of Ruling Out an Underlying Cause Before Treatment of AIHA
-
Apr 6, 2026, 10:49Chokri Ben Lamine: Routine VTE Prophylaxis Is Not Recommended for Chronically Bedridden Patients at Home
-
Apr 6, 2026, 10:03Mohamed Sikkander Abdul Razak: Clinical Steps for Evaluating and Managing Heavy Menstrual Bleeding
-
Apr 6, 2026, 07:14Oliver Tiebel: Antiphospholipid Syndrome in Pregnancy – One of Hematology’s Most Complex Challenges
-
Apr 6, 2026, 06:25Katherine Bridge: My First Time at The EHA ReCon
-
Apr 6, 2026, 06:11Priya Prasad: Family Donations Are Not as Safe as We Usually Think
-
Apr 6, 2026, 05:48Isaac Okello: Turning Point from Reliance on Foreign Exports to Self – Reliance Through Local Production of Medical Supplies